Ensuring Pharmacovigilance Compliance and Patient Safety Through Structured Medical Writing
Customer Requirement
A pharmaceutical company needed to put together a Risk Management Plan (RMP) for one of its medicinal products as part of its initial application for marketing authorisation.
The RMP had to lay out a clear, science-backed approach to spotting and managing both known and potential risks tied to the product. It also needed to cover gaps in available information at the time of authorisation, and set out what the Marketing Authorisation Holder (MAH) planned to do, in terms of pharmacovigilance activities and risk-minimisation measures, to keep a close eye on safety, pick up on any new concerns early, and keep the chance or impact of adverse reactions as low as possible, all in the interest of patients using the product safely and effectively.
Problem Statement
The client had previously submitted an RMP to the regulatory authority, which was rejected. The initial document failed to meet the agency’s expectations for scientific rigour, structural compliance, and completeness of safety data characterisation resulting in a significant regulatory setback and risk of delayed market entry.
The RMP is mandated in a range of regulatory scenarios, including:
- At initial marketing authorisation application for all medicinal products.
- With applications for significant variations or extensions, such as new indications, new routes of administration, or new target populations (e.g., paediatric use).
- Following major changes to the manufacturing process that may impact the benefit–risk profile.
- When important new safety concerns are identified, including the emergence of new risks, changes to the severity or frequency of known risks, or identification of missing information.
- At the request of regulatory authorities, for example, following a signal evaluation, periodic safety review, or pharmacovigilance inspection.
Bringing all of this together, nonclinical data, clinical findings, and real-world post-marketing experience into one well-structured, regulator-ready document is no small task. That’s where the client needed specialist medical writing support: to make sure the RMP was thorough, scientifically sound, and built to hold up under regulatory review.
Key Objective
The goal was to put together a thorough, GVP Module V-compliant Risk Management Plan, one that accurately reflects the product’s safety profile, meets regulatory requirements, and gets accepted by the authority on time, making up for the submission that had previously been turned down.
Getting there meant keeping a few things front and centre: staying on top of regulatory requirements, maintaining scientific accuracy, and hitting deadlines without cutting corners on quality or clarity. It also meant being proactive about any gaps in the data, sticking to the agreed timelines, and making sure feedback from the client and across teams was actually picked up and acted on throughout the drafting process.
Regulatory Support and Outcome
DDReg collected and analysed the required safety data and compiled the RMP in line with GVP Module V requirements, covering the safety specification, pharmacovigilance plan, and risk minimisation measures.
The completed RMP was submitted to the regulatory authority during the initial marketing authorisation application. The client’s earlier submission had been rejected; the RMP prepared by DDReg was submitted and accepted by the regulatory authority.
Business Impact
1 | Previously rejected RMP revised and accepted by the regulatory authority. |
2 | Marketing authorisation pathway restored following an earlier regulatory setback. |
3 | Safety characterisation covering identified risks, potential risks, and missing information. |
4 | Compliance with GVP Module V and agency-specific guidance maintained throughout. |
5 | RMP delivered within agreed timelines, supporting the client’s submission schedule. |
Key Learning
A well-prepared RMP is important to achieving marketing authorisation. Scientific accuracy, regulatory compliance, and timely delivery are key factors in ensuring the document meets agency expectations and supports a successful submission.